Hørsholm-based T-cellic's strategy is to use activated T-cells to carry imaging agents and anti-cancer compounds. The company has developed proprietary techniques for extracting specific T-cell populations from blood, culturing those cells to ensure adequate supply, conjugating imaging agents or therapeutics to the T-cells, and successfully re-introducing the modified T-cells to the body.

Summarizing the month in European dealmaking.